Middle East Respiratory Syndrome Coronavirus

Jaffar A. Al-Tawfiq; Esam I. Azhar; Ziad A. Memish; Alimuddin Zumla

doi:10.1055/s-0041-1733804

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2021; 42(06): 828-838
DOI: 10.1055/s-0041-1733804

Review Article

Middle East Respiratory Syndrome Coronavirus

Jaffar A. Al-Tawfiq

¹Infectious Disease Unit, Specialty Internal Medicine, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia

²Division of Infectious Disease, Indiana University School of Medicine, Indianapolis, Indiana

³Division of Infectious Disease, Johns Hopkins University, Baltimore, Maryland

,

Esam I. Azhar

⁴Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia

,

Ziad A. Memish

⁵Research and Innovation Centre, King Saud Medical City, Ministry of Health and College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

⁶Hubert Department of Global Health, Emory University, Atlanta, Georgia

,

Alimuddin Zumla

⁷Division of Infection and Immunity, Department of Infection, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom

› Institutsangaben

Abstract

The past two decades have witnessed the emergence of three zoonotic coronaviruses which have jumped species to cause lethal disease in humans: severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2. MERS-CoV emerged in Saudi Arabia in 2012 and the origins of MERS-CoV are not fully understood. Genomic analysis indicates it originated in bats and transmitted to camels. Human-to-human transmission occurs in varying frequency, being highest in healthcare environment and to a lesser degree in the community and among family members. Several nosocomial outbreaks of human-to-human transmission have occurred, the largest in Riyadh and Jeddah in 2014 and South Korea in 2015. MERS-CoV remains a high-threat pathogen identified by World Health Organization as a priority pathogen because it causes severe disease that has a high mortality rate, epidemic potential, and no medical countermeasures. MERS-CoV has been identified in dromedaries in several countries in the Middle East, Africa, and South Asia. MERS-CoV-2 causes a wide range of clinical presentations, although the respiratory system is predominantly affected. There are no specific antiviral treatments, although recent trials indicate that combination antivirals may be useful in severely ill patients. Diagnosing MERS-CoV early and implementation infection control measures are critical to preventing hospital-associated outbreaks. Preventing MERS relies on avoiding unpasteurized or uncooked animal products, practicing safe hygiene habits in health care settings and around dromedaries, community education and awareness training for health workers, as well as implementing effective control measures. Effective vaccines for MERS-COV are urgently needed but still under development.

Keywords

coronavirus - epidemic infections - MERS coronavirus

Volltext

Referenzen

References
1 Lee N, Hui D, Wu A. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348 (20) 1986-1994
2 Shaw K. The 2003 SARS outbreak and its impact on infection control practices. Public Health 2006; 120 (01) 8-14
3 Graham RL, Baric RS. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol 2010; 84 (07) 3134-3146
4 Leung GM, Hedley AJ, Ho L-M. et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004; 141 (09) 662-673
5 Tsang KW, Ho PL, Ooi GC. et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348 (20) 1977-1985
6 Poutanen SM, Low DE, Henry B. et al; National Microbiology Laboratory, Canada, Canadian Severe Acute Respiratory Syndrome Study Team. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003; 348 (20) 1995-2005
7 Centers for Disease Control and Prevention (CDC). Outbreak of severe acute respiratory syndrome--worldwide, 2003. MMWR Morb Mortal Wkly Rep 2003; 52 (11) 226-228
8 Centers for Disease Control and Prevention (CDC). Preliminary clinical description of severe acute respiratory syndrome. MMWR Morb Mortal Wkly Rep 2003; 52 (12) 255-256
9 Centers for Disease Control and Prevention (CDC). Update: severe acute respiratory syndrome--United States, June 4, 2003. MMWR Morb Mortal Wkly Rep 2003; 52 (22) 525-526
10 Centers for Disease Control and Prevention (CDC). Severe acute respiratory syndrome (SARS) and coronavirus testing--United States, 2003. Morb Mortal Wkly Rep 2003; 52 (14) 297-302
11 Centers for Disease Control and Prevention (CDC). Severe acute respiratory syndrome--Singapore, 2003. Morb Mortal Wkly Rep 2003; 52 (18) 405-411
12 Parashar UD, Anderson LJ. Severe acute respiratory syndrome: review and lessons of the 2003 outbreak. Int J Epidemiol 2004; 33 (04) 628-634
13 Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367 (19) 1814-1820
14 Corman VM, Eckerle I, Bleicker T. et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012; 17 (39) 17
15 de Groot RJ, Baker SC, Baric RS. et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013; 87 (14) 7790-7792
16 Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY, Yuen K-Y. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015; 28 (02) 465-522
17 Drosten C, Günther S, Preiser W. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348 (20) 1967-1976
18 van Boheemen S, de Graaf M, Lauber C. et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012; 3 (06) e00473-e12
19 Kim YS, Aigerim A, Park U. et al. Sequential emergence and wide spread of neutralization escape middle east respiratory syndrome coronavirus mutants, South Korea, 2015. Emerg Infect Dis 2019; 25 (06) 1161-1168
20 Leung GM, Lim WW, Ho LM. et al. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. Epidemiol Infect 2006; 134 (02) 211-221
21 Cheng VCC, Lau SKP, Woo PCY, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007; 20 (04) 660-694
22 Haagmans BL, Al Dhahiry SHS, Reusken CBEM. et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2014; 14 (02) 140-145
23 Adney DR, van Doremalen N, Brown VR. et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis 2014; 20 (12) 1999-2005
24 Azhar EI, El-Kafrawy SA, Farraj SA. et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014; 370 (26) 2499-2505
25 Nowotny N, Kolodziejek J. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels, Oman, 2013. Euro Surveill 2014; 19 (16) 20781
26 Conzade R, Grant R, Malik MR. et al. Reported direct and indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases. Viruses 2018; 10 (08) 425
27 Kandeil A, Gomaa M, Nageh A. et al. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Africa and Middle East. Viruses 2019; 11 (08) 717
28 Reusken CB, Farag EA, Jonges M. et al. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. Euro Surveill 2014; 19 (23) 20829
29 van Doremalen N, Hijazeen ZSK, Holloway P. et al. High prevalence of Middle East respiratory coronavirus in young dromedary camels in Jordan. Vector Borne Zoonotic Dis 2017; 17 (02) 155-159
30 Hemida MG, Elmoslemany A, Al-Hizab F. et al. Dromedary camels and the transmission of Middle East respiratory syndrome coronavirus (MERS-CoV). Transbound Emerg Dis 2017; 64 (02) 344-353
31 Rabaan AA, Bazzi AM, Al-Ahmed SH, Al-Tawfiq JA. Molecular aspects of MERS-CoV. Front Med 2017; 11 (03) 365-377
32 Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus: epidemiology and disease control measures. Infect Drug Resist 2014; 7: 281-287
33 Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol 2020; 92 (04) 433-440
34 Kuhn JH, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol Life Sci 2004; 61 (21) 2738-2743
35 Li W, Moore MJ, Vasilieva N. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426 (6965): 450-454
36 Te N, Vergara-Alert J, Lehmbecker A. et al. Co-localization of Middle East respiratory syndrome coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract and lymphoid tissues of pigs and llamas. Transbound Emerg Dis 2019; 66 (02) 831-841
37 Raj VS, Mou H, Smits SL. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495 (7440): 251-254
38 van Doremalen N, Miazgowicz KL, Milne-Price S. et al. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol 2014; 88 (16) 9220-9232
39 Assiri A, McGeer A, Perl TM. et al; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369 (05) 407-416
40 WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) WHO MERS-CoV Global Summary and Assessment of Risk Global summary. 2017 . Accessed January 5, 2021 at: http://www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf?ua=1
41 Memish ZA, Mishra N, Olival KJ. et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013; 19 (11) 1819-1823
42 Reusken CBEM, Haagmans BL, Müller MA. et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013; 13 (10) 859-866
43 Reusken CB, Ababneh M, Raj VS. et al. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill 2013; 18 (50) 20662
44 Hemida MG, Perera RA, Wang P. et al. Middle East respiratory syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill 2013; 18 (50) 20659
45 Alexandersen S, Kobinger GP, Soule G, Wernery U. Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. Transbound Emerg Dis 2014; 61 (02) 105-108
46 Reusken CBEM, Messadi L, Feyisa A. et al. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg Infect Dis 2014; 20 (08) 1370-1374
47 Corman VM, Jores J, Meyer B. et al. Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013. Emerg Infect Dis 2014; 20 (08) 1319-1322
48 Hemida MG, Alnaeem A, Chu DK. et al. Longitudinal study of Middle East respiratory syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014-2015. Emerg Microbes Infect 2017; 6 (06) e56
49 Wernery U, Corman VM, Wong EYM. et al. Acute Middle East respiratory syndrome coronavirus infection in livestock Dromedaries, Dubai, 2014. Emerg Infect Dis 2015; 21 (06) 1019-1022
50 Khalafalla AI, Lu X, Al-Mubarak AI, Dalab AH, Al-Busadah KA, Erdman DD. MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013-2014. Emerg Infect Dis 2015; 21 (07) 1153-1158
51 Farag EABA, Reusken CBEM, Haagmans BL. et al. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. Infect Ecol Epidemiol 2015; 5: 28305
52 Raj VS, Farag EABA, Reusken CBEM. et al. Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. Emerg Infect Dis 2014; 20 (08) 1339-1342
53 Yusof MF, Eltahir YM, Serhan WS. et al. Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates. Virus Genes 2015; 50 (03) 509-513
54 Alagaili AN, Briese T, Mishra N. et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 2014; 5 (02) e00884-e14
55 Hemida MG, Chu DKW, Poon LLM. et al. MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg Infect Dis 2014; 20 (07) 1231-1234
56 Briese T, Mishra N, Jain K. et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. MBio 2014; 5 (03) e01146-e14
57 Memish ZA, Cotten M, Meyer B. et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg Infect Dis 2014; 20 (06) 1012-1015
58 Al Hammadi ZM, Chu DKW, Eltahir YM. et al. Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015. Emerg Infect Dis 2015; 21 (12) 2197-2200
59 WHO. WHO | Revised interim case definition for reporting to WHO – Middle East respiratory syndrome coronavirus (MERS-CoV). WHO 2013. 2015 . Accessed January 5, 2021 at: http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/index.html
60 WHO MERS-CoV Research Group. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 2013; 5: 5
61 Omrani AS, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, Albarrak AM. A family cluster of Middle East respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 2013; 17 (09) e668-e672
62 Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013; 368 (26) 2487-2494
63 Memish ZA, Cotten M, Watson SJ. et al. Community case clusters of Middle East respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study. Int J Infect Dis 2014; 23: 63-68
64 Drosten C, Muth D, Corman VM. et al. An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014. Clin Infect Dis 2015; 60 (03) 369-377
65 Memish ZA, Al-Tawfiq JA, Alhakeem RF. et al. Middle East respiratory syndrome coronavirus (MERS-CoV): a cluster analysis with implications for global management of suspected cases. Travel Med Infect Dis 2015; 13 (04) 311-314
66 El Bushra HE, Abdalla MN, Al Arbash H. et al. An outbreak of Middle East respiratory syndrome (MERS) due to coronavirus in Al-Ahssa Region, Saudi Arabia, 2015. East Mediterr Health J 2016; 22 (07) 468-475
67 Balkhy HH, Alenazi TH, Alshamrani MM. et al. Notes from the field: nosocomial outbreak of Middle East respiratory syndrome in a large tertiary care hospital--Riyadh, Saudi Arabia, 2015. MMWR Morb Mortal Wkly Rep 2016; 65 (06) 163-164
68 Balkhy HH, Alenazi TH, Alshamrani MM. et al. Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol 2016; 37 (10) 1147-1155
69 Assiri AM, Biggs HM, Abedi GR. et al. Increase in Middle East respiratory syndrome-coronavirus cases in Saudi Arabia linked to hospital outbreak with continued circulation of recombinant virus, July 1-August 31, 2015. Open Forum Infect Dis 2016; 3 (03) ofw165
70 Nazer RI. Outbreak of Middle East respiratory syndrome-coronavirus causes high fatality after cardiac operations. Ann Thorac Surg 2017; 104 (02) e127-e129
71 Assiri A, Abedi GR, Bin Saeed AA. et al. Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia. Emerg Infect Dis 2016; 22 (01) 32-40
72 Hunter JC, Nguyen D, Aden B. et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis 2016; 22 (04) 647-656
73 Cauchemez S, Van Kerkhove MD, Riley S, Donnelly CA, Fraser C, Ferguson NM. Transmission scenarios for Middle East respiratory syndrome coronavirus (MERS-CoV) and how to tell them apart. Euro Surveill 2013; 18 (24) 20503
74 Cauchemez S, Fraser C, Van Kerkhove MD. et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis 2014; 14 (01) 50-56
75 Al-Abdallat MM, Payne DC, Alqasrawi S. et al; Jordan MERS-CoV Investigation Team. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014; 59 (09) 1225-1233
76 Chowell G, Abdirizak F, Lee S. et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med 2015; 13: 210
77 Hijawi B, Abdallat M, Sayaydeh A. et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J 2013; 19 (Suppl. 01) S12-S18
78 Al-Tawfiq JA, Memish ZA. Drivers of MERS-CoV transmission: what do we know?. Expert Rev Respir Med 2016; 10 (03) 331-338
79 Oboho IK, Tomczyk SM, Al-Asmari AM. et al. 2014 MERS-CoV outbreak in Jeddah--a link to health care facilities. N Engl J Med 2015; 372 (09) 846-854
80 Alraddadi B, Bawareth N, Omar H. et al. Patient characteristics infected with Middle East respiratory syndrome coronavirus infection in a tertiary hospital. Ann Thorac Med 2016; 11 (02) 128-131
81 Fagbo SF, Skakni L, Chu DKW. et al. Molecular epidemiology of hospital outbreak of Middle East respiratory syndrome, Riyadh, Saudi Arabia, 2014. Emerg Infect Dis 2015; 21 (11) 1981-1988
82 Almekhlafi GA, Albarrak MM, Mandourah Y. et al. Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients. Crit Care 2016; 20 (01) 123
83 Saad M, Omrani AS, Baig K. et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014; 29: 301-306
84 Barry M, Phan MV, Akkielah L. et al. Nosocomial outbreak of the Middle East respiratory syndrome coronavirus: a phylogenetic, epidemiological, clinical and infection control analysis. Travel Med Infect Dis 2020; 37: 101807
85 Bernard-Stoecklin S, Nikolay B, Assiri A. et al. Comparative analysis of eleven healthcare-associated outbreaks of Middle East respiratory syndrome coronavirus (MERS-CoV) from 2015 to 2017. Sci Rep 2019; 9 (01) 7385
86 WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update–as of 9 May 2014. Accessed January 5, 2021 at: http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf?ua=1
87 WHO. WHO update and clarification on recent MERS cases reported by the Kingdom of Saudi Arabia 23 June 2016. WHO 2016. Accessed January 5, 2021 at: http://who.int/emergencies/mers-cov/saudi-arabia-update/en/
88 Alenazi TH, Al Arbash H, El-Saed A. et al. Identified transmission dynamics of Middle East respiratory syndrome coronavirus infection during an outbreak: implications of an overcrowded emergency department. Clin Infect Dis 2017; 65 (04) 675-679
89 WHO. Middle East respiratory syndrome coronavirus (MERS-CoV): Summary and Risk Assessment of Current Situation in the Republic of Korea and China – as of 19 June 2015. Accessed January 5, 2021 at: http://www.who.int/emergencies/mers-cov/mers-cov-republic-of-korea-and-china-risk-assessment-19-june-2015.pdf?ua=1
90 Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill 2015; 20 (Suppl. 25) 7-13
91 Kim Y, Lee S, Chu C, Choe S, Hong S, Shin Y. The characteristics of Middle Eastern respiratory syndrome coronavirus transmission dynamics in South Korea. Osong Public Health Res Perspect 2016; 7 (01) 49-55
92 WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) WHO MERS-CoV Global Summary and risk assessment Global summary December 2016. Accessed January 5, 2021 at: http://www.who.int/emergencies/mers-cov/mers-summary-2016.pdf
93 Park Y-S, Lee C, Kim KM. et al. The first case of the 2015 Korean Middle East respiratory syndrome outbreak. Epidemiol Health 2015; 37: e2015049
94 Park HY, Lee EJ, Ryu YW. et al. Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Euro Surveill 2015; 20 (25) 1-6
95 Kim KH, Tandi TE, Choi JW, Moon JM, Kim MS. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect 2017; 95 (02) 207-213
96 Nishiura H, Endo A, Saitoh M. et al. Identifying determinants of heterogeneous transmission dynamics of the Middle East respiratory syndrome (MERS) outbreak in the Republic of Korea, 2015: a retrospective epidemiological analysis. BMJ Open 2016; 6 (02) e009936
97 Oh MD, Choe PG, Oh HS. et al. Middle East respiratory syndrome coronavirus superspreading event involving 81 persons, Korea 2015. J Korean Med Sci 2015; 30 (11) 1701-1705
98 Hastings DL, Tokars JI, Abdel Aziz IZAM. et al. Outbreak of Middle East respiratory syndrome at tertiary care hospital, Jeddah, Saudi Arabia, 2014. Emerg Infect Dis 2016; 22 (05) 794-801
99 Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle East respiratory syndrome. Lancet 2020; 395 (10229): 1063-1077
100 Shalhoub S, Farahat F, Al-Jiffri A. et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015; 70 (07) 2129-2132
101 Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect 2015; 6 (04) 269-278
102 Al-Tawfiq JA, Gautret P. Asymptomatic Middle East respiratory syndrome coronavirus (MERS-CoV) infection: extent and implications for infection control: a systematic review. Travel Med Infect Dis 2019; 27: 27-32
103 Assiri A, Al-Tawfiq JA, Al-Rabeeah AA. et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13 (09) 752-761
104 Nam H-S, Park JW, Ki M, Yeon M-Y, Kim J, Kim SW. High fatality rates and associated factors in two hospital outbreaks of MERS in Daejeon, the Republic of Korea. Int J Infect Dis 2017; 58: 37-42
105 Al-Tawfiq JA, Alfaraj SH, Altuwaijri TA, Memish ZA. A cohort-study of patients suspected for MERS-CoV in a referral hospital in Saudi Arabia. J Infect 2017; 75 (04) 378-379
106 Choi WS, Kang C-I, Kim Y. et al; Korean Society of Infectious Diseases. Clinical presentation and outcomes of Middle East respiratory syndrome in the Republic of Korea. Infect Chemother 2016; 48 (02) 118-126
107 Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus in the last two years: health care workers still at risk. Am J Infect Control 2019; 47 (10) 1167-1170
108 Al-Tawfiq JA, Hinedi K, Ghandour J. et al. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 2014; 59 (02) 160-165
109 Arabi YM, Arifi AA, Balkhy HH. et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 2014; 160 (06) 389-397
110 Al-Tawfiq JA, Auwaerter PG. Healthcare-associated infections: the hallmark of Middle East respiratory syndrome coronavirus with review of the literature. J Hosp Infect 2019; 101 (01) 20-29
111 Alfaraj SH, Al-Tawfiq JA, Gautret P, Alenazi MG, Asiri AY, Memish ZA. Evaluation of visual triage for screening of Middle East respiratory syndrome coronavirus patients. New Microbes New Infect 2018; 26: 49-52
112 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
113 Al-Hameed F, Wahla AS, Siddiqui S. et al. Characteristics and outcomes of Middle East respiratory syndrome coronavirus patients admitted to an intensive care unit in Jeddah, Saudi Arabia. J Intensive Care Med 2016; 31 (05) 344-348
114 Leung CW, Chiu WK. Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children. Paediatr Respir Rev 2004; 5 (04) 275-288
115 Memish ZAZA, Al-Tawfiq JAJA, Assiri A. et al. Middle East respiratory syndrome coronavirus disease in children. Pediatr Infect Dis J 2014; 33 (09) 904-906
116 Al-Tawfiq JA, Kattan RF, Memish ZA. Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia. World J Clin Pediatr 2016; 5 (04) 391-396
117 Thabet F, Chehab M, Bafaqih H, Al Mohaimeed S. Middle East respiratory syndrome coronavirus in children. Saudi Med J 2015; 36 (04) 484-486
118 Memish ZA, Al-Tawfiq JA, Makhdoom HQ. et al. Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study. Clin Microbiol Infect 2014; 20 (05) 469-474
119 Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, Memish ZA. Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia. Front Med 2019; 13 (01) 126-130
120 Denison MR. Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: an update. Pediatr Infect Dis J 2004; 23 (11, Suppl): S207-S214
121 Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus intermittent positive cases: implications for infection control. Am J Infect Control 2019; 47 (03) 290-293
122 Liu S, Chan T-C, Chu Y-T. et al. Comparative epidemiology of human infections with Middle East respiratory syndrome and severe acute respiratory syndrome coronaviruses among healthcare personnel. PLoS One 2016; 11 (03) e0149988
123 Penttinen PM, Kaasik-Aaslav K, Friaux A. et al. Taking stock of the first 133 MERS coronavirus cases globally--Is the epidemic changing?. Euro Surveill 2013; 18 (39) 18
124 Ahmed AE. The predictors of 3- and 30-day mortality in 660 MERS-CoV patients. BMC Infect Dis 2017; 17 (01) 615
125 Arabi YM, Mandourah Y, Al-Hameed F. et al; Saudi Critical Care Trial Group. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018; 197 (06) 757-767
126 Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of Middle East respiratory syndrome coronavirus (MERS-CoV) infection: a cohort study. Travel Med Infect Dis 2019; 29: 48-50
127 Cha R-H, Joh J-S, Jeong I. et al; Critical Care Team of National Medical Center. Renal complications and their prognosis in Korean patients with Middle East respiratory syndrome-coronavirus from the central MERS-CoV designated hospital. J Korean Med Sci 2015; 30 (12) 1807-1814
128 Arabi YM, Al-Omari A, Mandourah Y. et al; Saudi Critical Care Trial Group. Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med 2017; 45 (10) 1683-1695
129 Alshahrani MS, Sindi A, Alshamsi F. et al. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care 2018; 8 (01) 3
130 Peiris JSM, Chu CM, Cheng VCC. et al; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361 (9371): 1767-1772
131 Grant PR, Garson JA, Tedder RS, Chan PKS, Tam JS, Sung JJY. Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med 2003; 349 (25) 2468-2469
132 Ng EKO, Ng PC, Hon KLE. et al. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. Clin Chem 2003; 49 (12) 2085-2088
133 Ng EKO, Hui DS, Chan KCA. et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem 2003; 49 (12) 1976-1980
134 Poon LLM, Chan KH, Wong OK. et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 2003; 28 (03) 233-238
135 Kraaij-Dirkzwager M, Timen A, Dirksen K. et al; MERS-CoV Outbreak Investigation Team of the Netherlands. Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014. Euro Surveill 2014; 19 (21) 20817
136 Drosten C. Is MERS another SARS?. Lancet Infect Dis 2013; 13 (09) 727-728
137 Guan WD, Mok CKP, Chen ZL. et al. Characteristics of traveler with Middle East respiratory syndrome, China, 2015. Emerg Infect Dis 2015; 21 (12) 2278-2280
138 Omrani AS, Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction. Pathog Glob Health 2015; 109 (08) 354-362
139 Chan JFW, Yuan S, Kok KH. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395 (10223): 514-523
140 Sherbini N, Iskandrani A, Kharaba A, Khalid G, Abduljawad M, Al-Jahdali H. Middle East respiratory syndrome coronavirus in Al-Madinah City, Saudi Arabia: demographic, clinical and survival data. J Epidemiol Glob Health 2017; 7 (01) 29-36
141 Al-Tawfiq JA, Hinedi K, Abbasi S, Babiker M, Sunji A, Eltigani M. Hematologic, hepatic, and renal function changes in hospitalized patients with Middle East respiratory syndrome coronavirus. Int J Lab Hematol 2017; 39 (03) 272-278
142 Hart BJ, Dyall J, Postnikova E. et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95 (Pt 3): 571-577
143 de Wilde AH, Raj VS, Oudshoorn D. et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol 2013; 94 (Pt 8): 1749-1760
144 Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 2013; 3: 1686
145 Tawalah H, Al-Qabandi S, Sadiq M, Chehadeh C, Al-Hujailan G, Al-Qaseer M. The most effective therapeutic regimen for patients with severe Middle East respiratory syndrome coronavirus (MERS-CoV) infection. J Infect Dis Ther 2015; 03: 1-5
146 Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014; 20: 42-46
147 Omrani AS, Saad MM, Baig K. et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014; 14 (11) 1090-1095
148 Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013; 17 (10) e792-e798
149 Spanakis N, Tsiodras S, Haagmans BL. et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 2014; 44 (06) 528-532
150 Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. Antivir Ther 2015; 20 (01) 87-91
151 Al Ghamdi M, Alghamdi KM, Ghandoora Y. et al. Treatment outcomes for patients with Middle Eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis 2016; 16: 174
152 Arabi YM, Asiri AY, Assiri AM. et al; Saudi Critical Care Trials Group. Interferon Beta-1b and lopinavir-ritonavir for Middle East respiratory syndrome. N Engl J Med 2020; 383 (17) 1645-1656
153 Beigel JH, Voell J, Kumar P. et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis 2018; 18 (04) 410-418
154 Alhetheel A, Albarrag A, Shakoor Z. et al. Assessment of Th1/Th2 cytokines among patients with Middle East respiratory syndrome coronavirus infection. Int Immunol 2020; 32 (12) 799-804
155 Tirupathi R, Bharathidasan K, Palabindala V, Salim SA, Al-Tawfiq JA. Comprehensive review of mask utility and challenges during the COVID-19 pandemic. Infez Med 2020; 28 (Suppl. 01) 57-63
156 Corman VM, Albarrak AM, Omrani AS. et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 2016; 62 (04) 477-483
157 Drosten C, Meyer B, Müller MAM. et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med 2014; 371 (09) 828-835
158 Zhao J, Alshukairi AN, Baharoon SA. et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol 2017; 2 (14) eaan5393
159 Alshukairi AN, Khalid I, Ahmed WA. et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis 2016; 22 (06) 1113-1115
160 Modjarrad K, Roberts CC, Mills KT. et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 2019; 19 (09) 1013-1022
161 Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers - Full Text View - ClinicalTrials.gov n.d. Accessed March 26, 2021 at: https://clinicaltrials.gov/ct2/show/NCT03721718
162 Koch T, Dahlke C, Fathi A. et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis 2020; 20 (07) 827-838
163 Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS - Full Text View - ClinicalTrials.gov n.d. Accessed March 26, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04119440
164 Folegatti PM, Bittaye M, Flaxman A. et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis 2020; 20 (07) 816-826
165 A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002) - Full Text View - ClinicalTrials.gov n.d. Accessed March 26, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04170829
166 Study of Safety and Immunogenicity of BVRS-GamVac-Combi - Full Text View - ClinicalTrials.gov n.d. Accessed March 26, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04128059
167 Study of Safety and Immunogenicity of BVRS-GamVac - Full Text View - ClinicalTrials.gov n.d. Accessed March 26, 2021 at: https://clinicaltrials.gov/ct2/show/NCT04130594